MAIN STORY
Promising evidence, with an important statistical distinction
On October 22, Merck and Moderna published detailed data from INTerpath-001, a randomized phase 3 trial enrolling about 1,137 people with stage IIB–IV melanoma completely removed by surgery. Its primary endpoint was recurrence-free survival: how long people stayed alive without their cancer coming back. The reported 42% figure describes a reduction in relative risk over follow-up. It does not mean that 42% more patients were cured.
At approximately two years, 82.2% of participants receiving the combination were estimated to remain recurrence-free, compared with 70% receiving Keytruda alone. The companies also reported about a 38% reduction in the risk of distant metastasis or death. These outcomes merit attention, although the results should not be generalized to every patient or melanoma stage.
A vaccine built around each tumor’s genetic fingerprint
Unlike a vaccine intended to prevent infection, intismeran autogene is designed to treat a particular person’s existing cancer risk. Following surgery, a tumor sample is sequenced to identify mutations that may generate distinctive proteins called neoantigens.

















